Title: ERRATUM: Higher Risk Patients Benefit More After Conversion from Pioglitazone to Rosiglitazone: Presented at AACE
|
|
To print: Select File and then Print from your browser's menu Title: ERRATUM: Higher Risk Patients Benefit More After Conversion from Pioglitazone to Rosiglitazone: Presented at AACE |
|
"ERRATUM: Higher Risk Patients Benefit More After Conversion from Pioglitazone to Rosiglitazone: Presented at AACE" There was an error in the title of our DG Dispatch (May 4, 2006) based on a presentation at the American Association of Clinical Endocrinologists (AACE) annual meeting. The title should have stated as follows: Higher Risk Patients Benefit More After Conversion from Rosiglitazone to Pioglitazone We apologise to the manufacturer for having published inaccurate information on their product. We are committed to providing the most accurate, relevant and balanced information for physicians worldwide and have devoted considerable resources to ensuring this. We deeply regret this error. |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |